A1D5I

Macitentan

Created:2024-01-19
Last modified:  2024-11-11

Help

Find related ligands:

Chemical Details

Formal Charge0
Atom Count52
Chiral Atom Count0
Bond Count54
Aromatic Bond Count18
2D diagram of A1D5I
Toggle HydrogenToggle Labels

Chemical Component Summary

NameMacitentan
Systematic Name (OpenEye OEToolkits)6-[2-(5-bromanylpyrimidin-2-yl)oxyethoxy]-5-(4-bromophenyl)-~{N}-(propylsulfamoyl)pyrimidin-4-amine
FormulaC19 H20 Br2 N6 O4 S
Molecular Weight588.273
TypeNON-POLYMER

Chemical Descriptors

TypeProgramVersionDescriptor
SMILESCACTVS3.385CCCN[S](=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1c3ccc(Br)cc3
SMILESOpenEye OEToolkits2.0.7CCCNS(=O)(=O)Nc1c(c(ncn1)OCCOc2ncc(cn2)Br)c3ccc(cc3)Br
Canonical SMILESCACTVS3.385 CCCN[S](=O)(=O)Nc1ncnc(OCCOc2ncc(Br)cn2)c1c3ccc(Br)cc3
Canonical SMILESOpenEye OEToolkits2.0.7 CCCNS(=O)(=O)Nc1c(c(ncn1)OCCOc2ncc(cn2)Br)c3ccc(cc3)Br
InChIInChI1.06 InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)
InChIKeyInChI1.06 JGCMEBMXRHSZKX-UHFFFAOYSA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
DrugBank IDDB08932 
NameMacitentan
Groups approved
DescriptionMacitentan is a dual endothelin receptor antagonist used in the treatment of pulmonary arterial hypertension (PAH).[L35890] It was first approved by the FDA in 2013. Macitentan differs from its predecessor [bosentan] in part due to its lower risk of hepatotoxicity. A combination product (Opsynvi) comprising macitentan and [tadalafil] was approved in Canada in October 2021 for the treatment of PAH.[L39105] It was subsequently approved by the FDA in March 2024.[L50622]
Synonyms
  • Macitentanum
  • Macitentán
  • Macitentan
Brand Names
  • Yuvanci
  • Opsumit
  • Opsynvi
IndicationMacitentan, alone or in combination with [tadalafil], is indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) in adult patients of WHO functional class II to III .[L35890, L39105, L50622]
Categories
  • Amides
  • Antihypertensive Agents
  • Antihypertensives for Pulmonary Arterial Hypertension
  • Cytochrome P-450 CYP2C19 Substrates
  • Cytochrome P-450 CYP2C8 Substrates
ATC-Code
  • C02KX04
  • C02KX54
CAS number441798-33-0

Drug Targets

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License
NameTarget SequencePharmacological ActionActions
Endothelin-1 receptorMETLCLRASFWLALVGCVISDNPERYSTNLSNHVDDFTTFRGTELSFLVT...unknownantagonist
Endothelin receptor type BMQPPPSLCGRALVALVLACGLSRIWGEERGFPPDRATPLLQTAEIMTPPT...unknownantagonist
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 2C19MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...unknownsubstrate
Cytochrome P450 2C9MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDI...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL2103873
PubChem 16004692
ChEMBL CHEMBL2103873
ChEBI CHEBI:76607
CCDC/CSD VEMRAI